New nano-gel to protect children receiving chemotherapy from hearing loss
Curtin University researchers will test a new nano-gel they have created to protect children receiving…
Author Rachael Babin
Rachael Babin
Rachael Babin is a medical writer, communications expert, digital content producer and trained media host. Rachael co-founded The Oncology Network in 2014. She is Editor-in-Chief of Oncology News Australia, Publisher of The Oncology Newsletter and Host and Creator of The Oncology Podcast. Before creating The Oncology Network, Rachael worked for MOGA, COSA and an international academic publishing house.
Teletrials right on target
When it comes to cancer care, all things are not equal. That’s especially true for…
The OJC 66: ASCO 2022 GI ctDNA Special with Jeanne Tie
Today’s episode of The Oncology Journal Club podcast series is an ASCO 2022 Special… Craig…
ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein
A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise…
ASCO 2022: ctDNA may help identify the need for adjuvant therapy in stage II colon cancer
In patients with stage II colon cancer where cancer DNA was not present in the…
ASCO 2022: Lung cancer therapy could help patients live longer
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug…
ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas
Two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to…
ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy
Based on guidance from biomarker screening, patients who are 55 years of age and older…
ASCO 2022: High-dose ifosfamide demonstrated as a standard of care for recurrent and primary refractory ewing sarcoma
Use of high-dose ifosfamide (Ifex) was found to be superior for treating recurrent and primary refractory…
ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low HER2 expression levels
The use of trastuzumab deruxtecan (Enhertu), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared…